Neurogene posts FY2024 net loss $75.1M, cash $312.4M, NGN-401 gets EMA PRIME, trial updates

Neurogene Inc.

Cash and marketable securities $312.4M as of Dec 31, 2024; runway into H2 2027 to support NGN-401 registrational trial and pipeline.
R&D expenses $60.9M in FY2024 (up from $44.4M) on higher Rett trial costs and headcount; net loss $75.1M vs $36.3M prior year.
NGN-401 Phase 1/2 trial: dose fixed at 1E15 vg, age range expanded >11 years; received EMA PRIME designation.
Anticipated milestones: regulatory update on registrational plans in H1 2025; additional interim clinical data in H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.